Research overview
Liraglutide and Dulaglutide: Older GLP-1 Analogues vs Semaglutide and Tirzepatide
14 November 2026 · 6 min read
Two older analogues, one line of research
Liraglutide and dulaglutide belong to the first wave of GLP-1 analogues, molecules designed to stay active longer than the natural hormone. Human GLP-1 is broken down quickly in the body, so changing its sequence became the starting point for later designs. Both peptides are well described in the literature, and their structures make a convenient reference point for teams comparing newer generations of this family.
Both products are sold exclusively as reagents for scientific research, not for use in humans or animals. Below we outline how they differ, what is known about their duration of action in models, and where they sit next to semaglutide and tirzepatide.
Liraglutide: a fatty acid as anchor
Liraglutide is an analogue of human GLP-1 built from 31 amino acid residues. One arginine in its sequence is replaced by lysine, and at position 26 a palmitic acid (C16) chain is attached through a short linker made of glutamic acid. This process is called acylation, and it is what distinguishes liraglutide from the natural hormone.
The literature describes the fatty acid as an element that binds the molecule to plasma albumin. This binding slows the removal of the peptide from the circulation. The modification also hinders breakdown by the DPP-4 enzyme, which shortens the action of natural GLP-1 very quickly. In preclinical models, acylation remains one of the main ways of comparing the stability of incretin peptides.
Dulaglutide: Fc fusion instead of a lipid chain
Dulaglutide is built differently. Instead of a fatty acid chain, the GLP-1 analogue is genetically fused to the Fc fragment of an IgG4 antibody, joined by a short, flexible linker. The molecule consists of two identical chains, so it is clearly larger than a short peptide. Here too the GLP-1 sequence has been modified to make it harder for DPP-4 to act on it.
The Fc fragment is well known from antibody biology. In research on fusion proteins, it is linked to recycling of the molecule through the FcRn receptor, which lengthens the time the molecule remains in the body of a model. Dulaglutide is produced by biotechnological methods rather than chemical synthesis, so its quality control and handling differ from work with short peptides.
Half-life in models: hours versus days
The most important difference between these molecules concerns half-life, the time after which the concentration of a substance in blood falls by half. In clinical studies it was reported as over ten hours for liraglutide and as several days for dulaglutide. The difference follows from molecular architecture: one binds albumin, the other is a large protein protected by its Fc fragment.
In animal models the profile depends on the species and the conditions of the study, so values taken from different papers should be compared with great care. For experimental planning it is enough to remember the direction: liraglutide has a shorter half-life, dulaglutide a considerably longer one. This makes it possible to design a study that compares how the duration of receptor exposure affects the response of cells or tissues.
| Feature | Liraglutide | Dulaglutide |
|---|---|---|
| Molecule type | acylated peptide, 31 residues | fusion protein with IgG4 Fc fragment |
| Modification | palmitic acid chain (C16) | genetic fusion with Fc |
| Albumin binding | yes, through the lipid chain | indirect, through large molecular size |
| Half-life (order of magnitude) | hours | days |
| Form in the shop | lyophilisate | lyophilisate |
| Purity | ≥ 99% (HPLC), mass confirmed by MS | ≥ 99% (HPLC), mass confirmed by MS |
Against semaglutide and tirzepatide
Newer molecules developed the same ideas further. Semaglutide is also an acylated GLP-1 analogue, with a fatty acid chain attached through a linker. The literature describes its stability as clearly longer than liraglutide’s, which makes it a natural comparison point for projects with a longer observation window.
Tirzepatide goes one step further. It is an agonist of two receptors, GIP and GLP-1, and its molecule is also acylated. For research teams, liraglutide and dulaglutide remain convenient reference points. They show how a change in the way a molecule is modified affects its duration of action, before moving on to more complex systems such as combining several receptors in one molecule.
It is worth noting that comparisons between these molecules usually rely on in vitro studies and animal models, not on a single uniform dataset. Each paper may use different cell lines, measurement methods and observation times. Older molecules such as liraglutide and dulaglutide help here, because their structure and properties are described in many independent sources. That makes it easier to anchor new results to a known starting point.
How to plan a comparison
The cleanest design uses two research arms with the same control group and identical culture or model conditions. The difference between the arms should come only from the structure of the molecule, so each peptide must come from a batch with confirmed purity and mass. Both molecules are at least 99% pure by HPLC, and their mass is confirmed by MS. We dispatch within 24 hours, with InPost parcel lockers in Poland and DPD couriers across Europe.
Adding several time points to the plan works better than a single reading. Since liraglutide and dulaglutide differ in duration of action in models, a measurement taken at one moment may distort the picture. A schedule with several readings shows whether the difference between arms grows, shrinks or stays constant. The conclusions then concern the structure of the molecule rather than a chance moment of measurement.
It is also worth recording in the protocol when and how the solution is prepared. Differences in stability also arise from handling, so the same preparation protocol should be applied to both peptides. If the comparison spans a longer period, note the opening date of each vial and the number of aliquots taken from it. Such an entry in the lab notebook makes it easier to explain unusual results later and to separate the effect of the molecule from the effects of handling.
Working in the lab
Store the lyophilisate at -20 °C, tightly closed and protected from light. Before opening a vial, let it reach room temperature to limit moisture condensing on the substance.
Carry out reconstitution with a sterile solvent, following aseptic practice. Keep the finished solution at 2-8 °C, avoid repeated freezing and thawing, and divide larger volumes into portions. Calculate the working concentration in the concentration calculator before starting the experiment, so that both arms have exactly the same concentration.